Commercial Expansion Strengthen US market presence by leveraging recent CCO and US General Manager appointments to accelerate commercialization of regenerative ECM products, pursue value-based selling with surgeons and hospital systems, and target complex wound care and soft tissue reconstruction segments.

Strategic Partnerships Leverage ongoing and past collaborations such as the TELA Bio partnership to co-develop advanced ECM solutions like OviTex, pursuing new co-development or distribution agreements in orthopedics, reconstructive surgery, and high-value wound care with Nasdaq-listed or large-cap partners.

Product Accessibility Highlight affordability and easy-to-use ECM-based products as a differentiator to drive adoption in mid to large healthcare systems, enabling mid-market hospitals and outpatient wound care centers to standardize regenerative healing protocols and reduce healing times.

Clinical & Education Focus Invest in clinician-focused demonstrations, case studies, and training programs to demonstrate improved outcomes in complex wounds, aligning with surgeon and nursing staff goals, which can elevate case volumes and expand theater, OR, and clinic usage.

Global Growth Signals Capitalize on international exposure through NZ Hi-Tech connectivity and a robust ECM platform to pursue geographic expansion opportunities, supported by a scalable cloud/ERP tech stack for rapid onboarding of new distributors and partners.